Spruce Biosciences' (SPRB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Spruce Biosciences (NASDAQ:SPRB), indicating ongoing concerns about the stock's performance.
• Recently, SPRB stock traded up to $176.36, with a notable market cap of $98.76 million, but it has shown significant volatility with a 12-month high of $240.00 and a low of $4.28.
• Spruce Biosciences is focused on developing novel therapies for rare endocrine disorders, specifically through their treatment candidate tildacerfont, which is currently in Phase 2b clinical trials.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

Spruce Biosciences Stock Performance

SPRB stock traded up $17.35 on Tuesday, hitting $176.36. 151,897 shares of the company's stock were exchanged, compared to its average volume of 157,306. The firm has a 50 day moving average price of $27.29 and a two-hundred day moving average price of $15.54. Spruce Biosciences has a 12-month low of $4.28 and a 12-month high of $240.00. The stock has a market cap of $98.76 million, a P/E ratio of -2.05 and a beta of 2.47.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.